Articles tagged with Drug Studies
A large-scale clinical trial has demonstrated that cannabis-based medication can effectively reduce the rate of relapse in individuals with cannabis dependency. Participants treated with nabiximols used significantly less illicit cannabis and showed improvements in physical and psychological well-being.
Rimegepant, a novel gepant therapy, demonstrates significant relief from acute migraine pain and associated symptoms in a large-scale clinical trial. The study found that rimegepant effectively blocks the CGRP pathway, providing a new option for people with migraine not helped by existing medications.
A new study suggests that larger drug trials are necessary for Alzheimer's disease due to the limitations of current trials. The researchers analyzed data from over 1,120 people with no cognitive difficulties and found a consistent pattern of cognitive development in those who had beta-amyloid in the brain.
Researchers at Pitt/UPMC are testing a technique called red cell exchange transfusion to prolong life and slow organ damage in sickle cell disease patients. The SCD-CARRE trial aims to determine whether red cell exchange can lower deaths and reduce hospitalizations.
A study at Boston Medical Center found that symptom-triggered medication dosing for neonatal opioid withdrawal syndrome reduces hospital stay length and unnecessary medication exposure. Infants treated with this approach had a median stay of 10.5 days, compared to 17 days for fixed-schedule treatment.
A new clinical trial will test the effects of the anti-obesity drug setmelanotide on participants with Bardet-Biedl syndrome or Alström syndrome, two rare genetic disorders that include obesity as a symptom. The trial aims to assess the drug's ability to lead to significant weight loss in these individuals.
A recent study found that decentralized collaboration in scientific research can increase the robustness of findings, particularly in drug-gene interactions. Independent groups using different methods are less prone to peer pressure and more likely to replicate results accurately.
A new study in Hawaii tallies nearly 82 human infections from the rat lungworm parasite over a decade, highlighting snails and slugs as primary carriers. Meanwhile, research on bednet monitoring reveals high variability in household use, which could be contributing to declining efficacy in malaria prevention.
A study at ESMO World Congress on Gastrointestinal Cancer 2019 found that a more flexible dosing regimen for regorafenib improves patients' quality of life while maintaining its efficacy. The reduced and intermittent dose groups showed numerical improvements in tolerance to side effects such as fatigue and hand-foot syndrome.
A review of studies indicates that pre-eclampsia can lead to persistent cardiovascular issues in women. Researchers are now calling for long-term cardiovascular screening for women with a history of the condition.
A type of blood pressure lowering medication called calcium-channel blocker may be linked to an increased risk of a bowel condition called diverticulosis. The study found that genetic variants related to this type of drug were associated with a higher risk of the condition.
The study demonstrated the potential of body-on-a-chip systems to transform the drug discovery process by accurately predicting cardiotoxic mechanisms and replicating in vivo results. The findings support the use of in vitro models to evaluate temporal pharmacokinetic/pharmacodynamic relationships.
Researchers from Mount Sinai highlight the importance of multidimensional data for stratifying a complex disease like asthma. Carefully designed, integrated multi-'omic' studies could accelerate precision medicine for asthma patients by defining asthma subtypes through transcriptomics and other omic approaches.
A new study found that one in five US adults experience harm because of someone else's drinking, with women more likely to report financial and family problems. Heavy drinking was linked to increased risk of harassment, threats, and driving-related harm.
A study of over 3,000 US counties found 412 high-risk areas with high opioid overdose mortality and low treatment capacity. Strategies to increase primary care clinician capacity and employment opportunities in these counties are recommended.
A review of 117 efforts to reduce low-value care found that most measured only the reduction of test and treatment use, while few assessed intended patient benefits or unintended consequences. Only half of ongoing studies aim to measure patient-reported outcomes, highlighting a need for more comprehensive evaluation.
Researchers found a consistent cholesterol-lowering effect for soy protein across all 46 trials, contradicting the FDA's proposed revocation of its health claim. The study's findings support the original FDA claim and highlight the benefits of incorporating soy into a plant-based diet.
A survey of orthopaedic providers found that they frequently recommend prescribing a nine-day supply of oxycodone after surgery, exceeding current guidelines. Despite knowledge gaps, the study highlights the need for evidence-based guidelines to curb overprescribing and patient harm.
The PHOENIx MDR-TB study compares the safety and efficacy of delamanid and isoniazid in preventing active MDR-TB disease in at-risk contacts. The trial will enroll approximately 5,610 participants across 12 countries.
Researchers at Lund University have made significant strides in developing a potential drug to combat preeclampsia, a life-threatening condition affecting millions of pregnant women worldwide. The study's findings confirm the therapeutic effects of alpha-1-microglobulin and suggest a promising path forward for patients with the disease.
A large multicentre randomised trial found no improvement in delivery rates with frozen embryo transfers compared to traditional fresh transfers. The study suggests that a general freeze-all strategy may not be beneficial for women with regular menstrual cycles.
Researchers call for long-term randomized deprescribing trials to explore whether reducing or eliminating anticholinergic medication use can improve cholinergic neurotransmission and reduce dementia risk. If successful, this approach could be a more feasible intervention than increasing physical activity or controlling diabetes.
A study published in JAMA Ophthalmology found that one-third of ophthalmic patients have discrepancies between clinician notes and EHR-generated medication lists. This inconsistency may lead to avoidable medication errors, threatening patient safety.
Researchers at Huntsman Cancer Institute discovered a new experimental drug, selinexor, which may block a crucial survival pathway exploited by myelofibrosis cells. A clinical trial has been designed to examine the drug's effectiveness in patients with myelofibrosis.
A new study found that even people with well-controlled epilepsy are at risk of sudden unexpected death in epilepsy (SUDEP). Researchers analyzed cases referred to the North American SUDEP Registry and found that sleep deprivation, skipping medication, and lack of seizure activity were common factors contributing to SUDEP.
A large-scale genetic study of diverse populations found that genetic mutations contributing to chronic diseases like diabetes vary across ethnicities. The research highlights the importance of including diverse populations in genetic studies to develop effective treatments for debilitating diseases.
A groundbreaking drug has shown significant growth benefits for children with achondroplasia, a genetic bone disorder affecting about one in every 25,000 infants. The four-year study found that the drug vosoritide increased height by up to 50% per year and was well-tolerated with no adverse effects on body proportion.
A four-year study found that vosoritide increased the average annual growth rate of children with achondroplasia by nearly 2 centimeters per year, bringing it close to average stature. The treatment also showed sustained effects and was generally well-tolerated.
A multicenter trial found that linagliptin reduced albuminuria but had no significant effect on eGFR or cardiovascular risk in patients with diabetes. The study also suggested that stratifying patients with nephrotic-range proteinuria could lead to better outcomes.
Researchers attach a removable lock to an arthritis drug to reduce systemic immune suppression and neutralization, making it safer and more effective. The modified form of the antibody shows promise in treating rheumatoid arthritis with fewer infections and less development of anti-infliximab antibodies.
Researchers tested a medication reservoir implant in 220 patients with wet age-related macular degeneration, finding it safe and effective in reducing the need for injections. The study showed significant improvements in eyesight, with patients able to see farther than before, and a longer time between refills.
A study analyzed medicine prices in Russia, finding a significant decrease since 2015, with generic prices nearing reference prices. Regulatory measures implemented in the Russian Federation have contributed to improving access to medicines.
The HOPE study demonstrates that low-dose prednisolone significantly improves pain symptoms and function in patients with painful hand osteoarthritis. The study found that prednisolone reduces synovitis and improves physical component scale and patient global assessment, making it a suitable target for treatment.
A systematic review found that serotonin and norepinephrine reuptake inhibitors (SNRIs) led to more harmful events compared to placebos in older adults. Antidepressants like SSRIs may increase the risk of falls, highlighting the need for careful consideration when prescribing these medications.
Researchers found that electronic inhaler monitoring, combined with a disease management program, reduced healthcare utilization in patients with COPD. The study showed a significant reduction in COPD-related hospitalizations and ER visits, from an average of 3.4 to 2.2 trips per year.
A team of UK scientists has identified the mechanism behind hardening of the arteries, which is associated with dementia, heart disease, high blood pressure, and stroke. They found that a generic medication normally used to treat acne could be an effective treatment for the condition.
A systematic review suggests that lithium's effects on breastfeeding are poorly understood due to sparse and poorly designed studies. Expert recommendations vary, and more research is necessary to inform patient decisions.
A clinical trial found that teplizumab, an immunotherapy drug, can delay the onset of type 1 diabetes in people at high risk. The study, published in the New England Journal of Medicine, showed a median delay of two years in children and adults.
Researchers review aspects of RA detection and intervention, highlighting potential for early screening and prevention. Studies discuss the development of effective preventive measures, which could significantly alter disease course and quality of life.
A randomized clinical trial found that patients taking IDegLira achieved and maintained lower blood glucose levels for longer periods compared to those taking insulin only. The study showed improved outcomes without the need for additional therapy, reducing side effects often associated with insulin-only treatment.
Researchers found that an immunotherapy treatment, teplizumab, effectively delayed the progression to clinical type 1 diabetes in high-risk individuals. Participants who received teplizumab took longer to develop clinical disease, with a median time of 48 months compared to just over 24 months for those in the control group.
A large international clinical trial found that dulaglutide reduced cardiovascular events by 12% and kidney disease by 15% in people with Type 2 diabetes. The study, REWIND, followed over 9,900 participants for five years.
A study of adults and youth with type 2 diabetes found that improvements in insulin release wane after treatment stops, highlighting the need for continued treatment. In contrast, youth experience more aggressive disease progression during and after treatment.
A large, multi-year randomized trial found no evidence to support claims that PPIs cause serious health issues such as pneumonia, chronic kidney disease, diabetes, and dementia. The study suggests that limiting prescriptions of PPI therapy is not appropriate due to the benefits outweighing the risks.
A new study found significant issues with non-medical use of alprazolam in the UK, particularly among younger adults. The estimated national prevalence of lifetime and recent use was 0.32% and 1.30%, respectively.
UC researchers present findings from the Belatacept Early Steroid Withdrawal Trial (BEST), showing that belatacept can safely and effectively treat kidney transplant patients. The study demonstrates reduced side effects and cardiovascular risk reduction compared to traditional immunosuppressive regimens.
A clinical trial found that galantamine reduced opioid positive urine samples and prolonged abstinence in participants. The medication's dual mechanism of action may offer new strategies for treating opioid use disorder.
The National Institutes of Health will fund clinical trials to assess genomic medicine interventions for managing diseases such as high blood pressure, depression, and chronic pain. The trials aim to improve treatment outcomes by tailoring drug prescriptions based on patients' genetic makeup.
A Phase II clinical trial conducted at MD Anderson Cancer Center revealed an 84.6% overall response rate and 38.5% complete response rate when combination targeted therapy was given prior to chemotherapy for newly diagnosed patients with a specific type of diffuse large B-cell lymphoma. The findings suggest that patients who respond to...
A new study has identified several potential approaches for improving medication adherence among Latinos with diabetes, including simple measures like pillboxes and family member education. The study also highlights specific challenges faced by underserved Latino communities, such as difficulty understanding medications and managing mu...
A study found that patients taking antihypertensive drugs had a decreased risk of developing dementia, with calcium channel blockers showing the most significant association. The study analyzed data from over 12,000 patients and suggested that these medications may help delay or reduce dementia onset.
The POLO trial shows that olaparib significantly reduces the risk of disease progression or death in metastatic pancreatic cancer patients with BRCA mutations. Progression-free survival was 7.4 months on the olaparib arm, compared to 3.8 months on the placebo arm.
Researchers at Fred Hutchinson Cancer Center have successfully treated cancer patients with HIV using immunotherapy drug pembrolizumab. The study found that the drug was safe and effective in patients with well-controlled HIV, offering hope for inclusivity in future clinical trials.
The NCI-MATCH trial found a combination of dabrafenib and trametinib to be effective in treating patients with BRAF mutations across 17 distinct tumor types, including several rare cancer types. The treatment showed promising activity outside of currently approved FDA indications.
A large study has demonstrated that enzalutamide improves outcomes for men with metastatic hormone-sensitive prostate cancer, with an overall survival rate of 80% after three years. This new treatment option is especially relevant for men who cannot tolerate chemotherapy and have a lower burden of disease.
Researchers developed COXEN, a predictive tool that analyzes gene expression to predict response to chemotherapy in bladder cancer patients. The trial showed COXEN's ability to predict response using Gemcitabine-Cisplatin (GC) biomarker.
Researchers suggest that cannabinoids may relieve symptoms of OCD and related disorders through targeting the endocannabinoid system. Animal study data and preliminary human clinical trial results support continued pharmaceutical development.
A virtual clinical trial using real-world data found entrectinib to be more effective than crizotinib in treating ROS1+ lung cancer. Patients on entrectinib stayed on treatment longer and had a 44% increased chance of cancer recurrence compared to those on crizotinib.
A study from Joslin Diabetes Center found that removing senescent beta-cells can recover their function and improve glucose metabolism in mice with insulin resistance. The researchers hope to develop a potential treatment using senolytics, which target aging cells contributing to disease dysfunction.
A new study presented at ASCO 2019 shows that brigatinib is effective in patients who have received another next-generation ALK inhibitor. The 40-50 percent response rate suggests that brigatinib may be a useful treatment option for these patients. Detailed molecular analyses will help determine the characteristics of patients sensitiv...